weight loss

Novo’s next-gen obesity drug misses expectations in closely watched trial
BioPharma Dive
Fri, 12/20/24 - 11:34 am
Novo Nordisk
CagriSema
clinical trials
weight loss
A new GLP-1 opportunity for pharma: Supporting patients’ emotional barriers to weight loss
Pharmaphorum
Wed, 12/18/24 - 11:14 am
patients
GLP-1 agonists
obesity
weight loss
Novo Nordisk
Eli Lilly
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
BioPharma Dive
Wed, 12/4/24 - 11:02 am
Eli Lilly
Zepbound
Novo Nordisk
Wegovy
clinical trials
weight loss
obesity
Weight-loss drug coverage rises among largest US employers, Mercer survey finds
MSN/Reuters
Wed, 11/20/24 - 11:30 am
employers
coverage
insurance
weight loss
obesity
Drugmakers and pharmacists battle over who gets to make obesity drugs
NPR
Wed, 11/20/24 - 11:21 am
Novo Nordisk
Eli Lilly
obesity
weight loss
GLP-1 agonists
compounded drugs
Novo’s Wegovy Launched in China at a Fraction of US Price
BioSpace
Mon, 11/18/24 - 11:28 am
Novo Nordisk
Wegovy
Cina
weight loss
GLP-1 agonists
Survey Finds Most GLP-1 Users Discontinue Drug Before Reaching Goal Weight
Xtalks
Fri, 11/15/24 - 11:27 am
Omada Health
GLP-1 agonists
obesity
weight loss
Novo Nordisk
Eli Lilly
Ozempic
Zepbound
Mounjaro
Wegovy
Eli Lilly’s weight-loss drug helps nearly 99% of patients remain diabetes-free
Pharma Live
Thu, 11/14/24 - 11:21 am
Eli Lilly
weight loss
tirzepatide
Mounjaro
Zepbound
diabetes
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Motley Fool
Thu, 10/17/24 - 09:24 am
Novartis
GLP-1 agonists
obesity
weight loss
Medicare coverage of weight loss drugs would cost $35B: CBO
The Hill
Wed, 10/9/24 - 08:56 pm
Medicare
obesity
weight loss
CBO
Weight loss gold rush: Developers vie for next blockbuster treatment
Pharmaphorum
Tue, 10/8/24 - 09:45 am
R&D
obesity
weight loss
Novo Nordisk
Eli Lilly
Roche
Boehringer Ingelheim
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
Forbes
Wed, 10/2/24 - 11:20 am
weight loss
obesity
GLP-1 agonist
Ozempic
Wegovy
Novo Nordisk
Zepbound
Mounjaro
Eli Lilly
Inside the GLP-1 'price war'
Beckers Hospital Review
Tue, 09/24/24 - 11:52 am
GLP-1 agonists
obesity
weight loss
Eli Lilly
Novo Nordisk
Ozempic
Wegovy
Zepbound
Mounjaro
drug pricing
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
Fierce Biotech
Fri, 09/20/24 - 11:30 am
Novo Nordisk
obesity
weight loss
clinical trials
Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
CNBC
Thu, 09/19/24 - 11:13 am
Novartis
Pharma CEOs
weight loss
obesity
Vas Narasimhan
Weight-loss market to see 16 new drugs by 2029, report estimates
Reuters
Tue, 09/10/24 - 04:29 pm
weight loss
obesity
Amgen
Pfizer
Roche
Novo Nordisk
Eli Lilly
Boehinger Ingelheim
Structure Therapeutics
Viking Therapeutics
Zealand Pharma
Altimmune
Lilly demands doctors stop selling copycat weight-loss drugs
Reuters
Thu, 08/15/24 - 11:50 am
Eli Lilly
drug counterfeiting
Zepbound
weight loss
Doctors struggle to get Wegovy for older Americans with heart disease
Reuters
Thu, 08/15/24 - 11:41 am
Novo Nordisk
Medicare
Wegovy
physicians
weight loss
Access is unequal to weight-loss drugs Ozempic and Wegovy: study
Axios
Mon, 08/5/24 - 11:08 am
Novo Nordisk
Ozempic
Wegovy
patient access
insurers
Medicaid
Medicare
weight loss
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
Motley Fool
Sun, 08/4/24 - 06:30 pm
AstraZeneca
Pharma CEOs
weight loss
obesity
Pascal Soriot

Pages